Wockhardt Ltd has decided to shut down its loss-making US generics business to channel its energy and funds into developing ...

The decision follows years of financial losses in the US generics business, including loss of nearly $8 million in FY 2025, ...

The state law gives Gov. Lamont "an enormous amount of negotiating leverage with the industry," Sen. Lesser said.

Wockhardt Ltd on July 11 said it has decided to exit US generic pharmaceutical segment to unlock capital for high-impact ...

This multi-state settlement addresses makers of generic versions of opioids and is up to $720 million, officials said.

Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to ...

Mumbai: Wockhardt has announced a significant strategic realignment of its U.S. business, marking an exit from the generic ...

The cover letter is more important than ever. In a world where AI can polish grammar and formatting, I use the cover letter ...

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

Far from the triumphant return to form DC and Warner Bros hoped for, James Gunn's 'Superman' is a generic, dull, overwritten ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...